| 92 | 0 | 216 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨分化簇53(CD53)通过Janus激酶2(JAK2)/信号转导及转录激活因子3(STAT3)/CD24信号轴在炎症环境下对泡沫细胞胞葬障碍的调控作用及其潜在分子机制。方法 提取小鼠腹腔巨噬细胞,将其与氧化型低密度脂蛋白共培养48 h诱导形成泡沫细胞。将泡沫细胞分为对照1组、联合脂多糖(LPS)/γ干扰素(IFN-γ)1组、LPS/IFN-γ+siCD53组(转染靶向CD53的siRNA沉默CD53),后两组以20 ng/mL IFN-γ预处理2 h、50 ng/mL LPS继续培养24 h构建炎症环境,并以0.1μmol/L地塞米松处理16 h诱导细胞凋亡。采用实时荧光定量PCR检测CD53及炎症因子白细胞介素1β(IL-1β)、IL-6、肿瘤坏死因子α(TNF-α)、单核细胞趋化蛋白1(MCP-1)mRNA表达;Western blotting检测CD53、CD24、磷酸化JAK2(p-JAK2)、磷酸化STAT3(p-STAT3)蛋白表达;流式细胞术检测巨噬细胞对凋亡泡沫细胞的胞葬作用。另设对照2组、LPS/IFN-γ 2组、LPS/IFN-γ+siCD24组,观察沉默CD24对凋亡泡沫细胞胞葬水平的影响。结果 与对照1组比较,LPS/IFN-γ 1组泡沫细胞CD53 mRNA和蛋白表达高(P均<0.05),IL-1β、IL-6、TNF-α、MCP-1 mRNA表达高(P均<0.05),胞葬水平低(P<0.05),CD24、p-JAK2、p-STAT3蛋白表达高(P均<0.05)。与LPS/IFN-γ 1组比较,LPS/IFN-γ+siCD53组CD53 mRNA和蛋白表达低(P均<0.05),炎症因子mRNA表达低(P均<0.05),胞葬水平高(P<0.05),CD24、p-JAK2、p-STAT3蛋白表达低(P均<0.05)。与LPS/IFN-γ2组比较,LPS/IFN-γ+siCD24组胞葬水平高(P<0.05)。结论 炎症环境下泡沫细胞CD53表达上调,沉默CD53可减轻炎症反应并逆转胞葬障碍;该作用可能与激活JAK2/STAT3信号通路上调CD24表达有关。
Abstract:Objective To investigate the regulatory role of cluster of differentiation 53(CD53) via the Janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3)/CD24 signaling axis in efferocytosis impairment of foam cells under inflammatory conditions and its potential molecular mechanisms.Methods Mouse peritoneal macrophages were extracted and co-cultured with oxidized low-density lipoprotein for 48 h to induce foam cell formation.The foam cells were divided into the control group 1,lipopolysaccharide(LPS)/interferon-γ(IFN-γ) group 1,and LPS/IFN-γ + siCD53 group(transfected with siRNA targeting CD53 to silence CD53).In the latter two groups,an inflammatory environment was established by pretreatment with 20 ng/mL IFN-γ for 2 h followed by 50 ng/mL LPS for 24 h,and apoptosis was induced by treatment with 0.1 μmol/L dexamethasone for 16 h.Real-time quantitative PCR was used to detect the mRNA expression of CD53 and inflammatory cytokines interleukin-1β(IL-1β),IL-6,tumor necrosis factor-α(TNF-α),and monocyte chemoattractant protein-1(MCP-1).Western blotting was performed to detect the protein expression of CD53,CD24,phosphorylated JAK2(p-JAK2),and phosphorylated STAT3(p-STAT3).Flow cytometry was used to assess the efferocytosis level of macrophages toward apoptotic foam cells.Additionally,LPS/IFN-γ group 2 and LPS/IFN-γ+siCD24 group were established to observe the effect of CD24 silencing on apoptotic foam cells and efferocytosis.Results Compared with the control group 1,the LPS/IFN-γ group 1 showed increased mRNA and protein expression levels of CD53 in foam cells(all P<0.05),elevated mRNA expression levels of IL-1β,IL-6,TNF-α,and MCP-1(all P<0.05),decreased efferocytosis level(P<0.05),and up-regulated protein expression levels of CD24,p-JAK2,and p-STAT3(all P<0.05).Compared with the LPS/IFN-γ group 1,the LPS/IFN-γ+siCD53 group exhibited decreased mRNA and protein expression levles of CD53(all P<0.05),reduced mRNA expression levels of inflammatory cytokines(all P<0.05),increased efferocytosis level(P<0.05),and down-regulated protein expression levels of CD24,p-JAK2,and p-STAT3(all P<0.05).Compared with the LPS/IFN-γ group 2,the LPS/IFN-γ+siCD24 group showed increased efferocytosis level(P<0.05).Conclusion CD53 expression is up-regulated in foam cells under inflammatory conditions,and silencing CD53 alleviates the inflammatory response and reverses efferocytosis impairment,possibly through activating the JAK2/STAT3 signaling pathway to up-regulate CD24 expression.
[1]WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019,124(2):315-327.
[2]KOJIMA Y, WEISSMAN I L, LEEPER N J. The role of efferocytosis in atherosclerosis[J]. Circulation, 2017,135(5):476-489.
[3]SCHRIJVERS D M, DE MEYER G R, KOCKX M M, et al.Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2005,25(6):1256-1261.
[4]SHU L X, CAO L L, GUO X, et al. Mechanism of efferocytosis in atherosclerosis[J]. J Mol Med(Berl), 2024,102(7):831-840.
[5]GERLACH B D, AMPOMAH P B, YURDAGUL A, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury[J]. Cell Metab, 2021,33(12):2445-2463.
[6]KUMMER D, STEINBACHER T, SCHWIETZER M F, et al.Tetraspanins:integrating cell surface receptors to functional microdomains in homeostasis and disease[J]. Med Microbiol Immunol, 2020,209(4):397-405.
[7]CAI S, DENG Y, PENG H, et al. Role of tetraspanins in hepatocellular carcinoma[J]. Front Oncol, 2021,11:723341.
[8]HIGGINS C B, ADAMS J A, WARD M H, et al. The tetraspanin transmembrane protein CD53 mediates dyslipidemia and integrates inflammatory and metabolic signaling in hepatocytes[J]. J Biol Chem, 2023,299(2):102835.
[9]MOLLINEDO F, FONTÁN G, BARASOAIN I, et al. Recurrent infectious diseases in human CD53 deficiency[J]. Clin Diagn Lab Immunol, 1997,4(2):229-231.
[10]UHLÉN M, FAGERBERG L, HALLSTRÖM B M, et al. Proteomics. Tissue-based map of the human proteome[J]. Science,2015,347(6220):1260419.
[11]DEMARIA M C, YEUNG L, PEETERS R, et al. Tetraspanin CD53 promotes lymphocyte recirculation by stabilizing l-selectin surface expression[J]. iScience, 2020,23(5):101104.
[12]GREENBERG Z J, MONLISH D A, BARTNETT R L, et al. The tetraspanin CD53 regulates early B cell development by promoting IL-7R signaling[J]. J Immunol, 2020,204(1):58-67.
[13]DURAN J, OLAVARRÍA P S, MOLA M, et al. Genetic association study of coronary collateral circulation in patients with coronary artery disease using 22 single nucleotide polymorphisms corresponding to 10 genes involved in postischemic neovascularization[J]. BMC Cardiovasc Disord, 2015,15:37.
[14]ZHAO B, WANG D, LIU Y, et al. Six-gene signature associated with immune cells in the progression of atherosclerosis discovered by comprehensive bioinformatics analyses[J]. Cardiovasc Ther,2020,2020:1230513.
[15]LIU C, ZHANG H, CHEN Y, et al. Identifying RBM47, HCK,CD53, TYROBP, and HAVCR2 as Hub genes in advanced atherosclerotic plaques by network-based analysis and validation[J]. Front Genet, 2020,11:602908.
[16]BARKAL A A, BREWER R E, MARKOVIC M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]. Nature, 2019,572(7769):392-396.
[17]CATALÁN R, OROZCO-MORALES M, HERNÁNDEZ-PEDRO N Y, et al. CD47-SIRPα axis as a biomarker and therapeutic target in cancer:current perspectives and future challenges in nonsmall cell lung cancer[J]. J Immunol Res, 2020,2020:9435030.
[18]KOJIMA Y, VOLKMER J P, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016,536(7614):86-90.
基本信息:
中图分类号:R543.5
引用信息:
[1]胡景堂,王珍,王鹏,等.基于JAK2/STAT3/CD24信号轴探讨CD53调控炎症环境下泡沫细胞胞葬障碍的机制[J].山东医药,2026,66(08):19-23.
基金信息:
四川省自然科学基金项目(2025ZNSFSC1702)
2026-08-05
2026-08-05
2026-08-05